|
1) Drossman DA, Dumitrascu DL. Rome III: New standard for functional gastrointestinal disorders. J Gastrointestin Liver Dis. 2006; 15: 237-41
|
|
|
|
2) Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. Gastroenterology. 2006; 130: 1466-79
|
|
|
|
|
|
3) Svedlund J, Sjodin I, Dotevall G. GSRS−a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci. 1988; 33: 129-34
|
|
|
|
|
4) Suzuki H, Nishizawa T, Hibi T. Therapeutic strategies for functional dyspepsia and the introduction of the Rome III classification. J Gastroenterol. 2006; 41: 513-23
|
|
|
|
|
5) National Institute for Clinical Excellence. The management of dyspepsia in adult patients in primary care. London: NICE. 2004;
|
|
|
|
|
|
6) Delaney BC, Qume M, Moayyedi P, et al. Helicobacter pylori test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: multicentre randomised controlled trial (MRC-CUBE trial). BMJ. 2008; 336: 651-4
|
|
|
|
|
|
7) Moayyedi P, Soo S, Deeks J, et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2006; CD002096
|
|
|
|
|
|
8) Suzuki H, Masaoka T, Sakai G, et al. Improvement of gastrointestinal quality of life scores in cases of Helicobacter pylori-positive functional dyspepsia after successful eradication therapy. J Gastroenterol Hepatol. 2005; 20: 1652-60
|
|
|
|
|
|
9) Moayyedi P, Soo S, Deeks J, et al. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2006; CD001960
|
|
|
|
|
|
10) Wang WH, Huang JQ, Zheng GF, et al. Effects of proton-pump inhibitors on functional dyspepsia: a meta-analysis of randomized placebo-controlled trials. Clin Gastroenterol Hepatol. 2007; 5: 178-85. quiz 140
|
|
|
|
|
|
11) Lee KJ, Kim JH, Cho SW. Dyspeptic symptoms associated with hypersensitivity to gastric distension induced by duodenal acidification. J Gastroenterol Hepatol. 2006; 21: 515-20
|
|
|
|
|
|
12) Lee KJ, Vos R, Janssens J, et al. Influence of duodenal acidification on the sensorimotor function of the proximal stomach in humans. Am J Physiol Gastrointest Liver Physiol. 2004; 286: G278-84
|
|
|
|
|
|
13) Halder SL, Talley NJ. Functional dyspepsia: A New Rome III paradigm. Curr Treat Options Gastroenterol. 2007; 10: 259-72
|
|
|
|
|
|
14) 本郷道夫. 日本人のFunctional Dyspepsia(FD)とJapan Mosapride Mega-Study(JMMS). 消化器心身医学. 2007; 14: 1-5
|
|
|
|
|
|
15) Holtmann G, Talley NJ, Liebregts T, et al. A placebo-controlled trial of itopride in functional dyspepsia. N Engl J Med. 2006; 354: 832-40
|
|
|
|
|
|
16) Talley NJ, Tack J, Ptak T, et al. Itopride in functional dyspepsia: results of two phase III multicentre, randomised, double-blind, placebo-controlled trials. Gut. 2008; 57: 740-6
|
|
|
|
|
|
17) Mearin F, Rodrigo L, Perez-Mota A, et al. Levosulpiride and cisapride in the treatment of dysmotility-like functional dyspepsia: a randomized, double-masked trial. Clin Gastroenterol Hepatol. 2004; 2: 301-8
|
|
|
|
|
|
18) Banani SJ, Lankarani KB, Taghavi A, et al. Comparison of metoclopramide oral tablets and solution in treatment of dysmotility-like dyspepsia. Am J Health Syst Pharm. 2008; 65: 1057-61
|
|
|
|
|
|
19) Miwa H, Osada T, Nagahara A, et al. Effect of a gastro-protective agent, rebamipide, on symptom improvement in patients with functional dyspepsia: a double-blind placebo-controlled study in Japan. J Gastroenterol Hepatol. 2006; 21: 1826-31
|
|
|
|
|
|
20) Hojo M, Miwa H, Yokoyama T, et al. Treatment of functional dyspepsia with antianxiety or antidepressive agents: systematic review. J Gastroenterol. 2005; 40: 1036-42
|
|
|
|
|
|
21) Tack J, Broekaert D, Coulie B, et al. Influence of the selective serotonin re-uptake inhibitor, paroxetine, on gastric sensorimotor function in humans. Aliment Pharmacol Ther. 2003; 17: 603-8
|
|
|
|
|
|
22) von Arnim U, Peitz U, Vinson B, et al. STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study. Am J Gastroenterol. 2007; 102: 1268-75
|
|
|
|
|
|
23) Holtmann G, Adam B, Haag S, et al. Efficacy of artichoke leaf extract in the treatment of patients with functional dyspepsia: a six-week placebo-controlled, double-blind, multicentre trial. Aliment Pharmacol Ther. 2003; 18: 1099-105
|
|
|
|
|
|
24) Kido T, Nakai Y, Kase Y, et al. Effects of rikkunshi-to, a traditional Japanese medicine, on the delay of gastric emptying induced by N(G)-nitro-L-arginine. J Pharmacol Sci. 2005; 98: 161-7
|
|
|
|
|
25) Alpers DH. Why should psychotherapy be a useful approach to management of patients with nonulcer dyspepsia？ Gastroenterology. 2000; 119: 869-71
|
|
|
|
|
|
26) Soo S, Moayyedi P, Deeks J, et al. Psychological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2005; CD002301
|
|
|
|
|
|
27) Saito YA, Locke GR. 3rd, Weaver AL, et al. Diet and functional gastrointestinal disorders: a population-based case-control study. Am J Gastroenterol. 2005; 100: 2743-8
|
|
|
|
|
|
28) Malatesta MG, Fascetti E, Ciccaglione AF, et al. 5-HT1-receptor agonist sumatriptan modifies gastric size after 500 ml of water in dyspeptic patients and normal subjects. Dig Dis Sci. 2002; 47: 2591-5
|
|
|
|
|
|
29) Seto K, Sasaki T, Katsunuma K, et al. Acotiamide hydrochloride (Z-338), a novel prokinetic agent, restores delayed gastric emptying and feeding inhibition induced by restraint stress in rats. Neurogastroenterol Motil. 2008; 20: 1051-9
|
|
|
|
|
|
30) Klupinska G, Poplawski T, Drzewoski J, et al. Therapeutic effect of melatonin in patients with functional dyspepsia. J Clin Gastroenterol. 2007; 41: 270-4
|
|
|
|
|
|
31) Sarnelli G, Sifrim D, Janssens J, et al. Influence of sildenafil on gastric sensorimotor function in humans. Am J Physiol Gastrointest Liver Physiol. 2004; 287: G988-92
|
|
|
|
|
|
32) Thumshirn M, Camilleri M, Choi MG, et al. Modulation of gastric sensory and motor functions by nitrergic and alpha2-adrenergic agents in humans. Gastroenterology. 1999; 116: 573-85
|
|
|
|
|
|
33) Tack J, Caenepeel P, Corsetti M, et al. Role of tension receptors in dyspeptic patients with hypersensitivity to gastric distention. Gastroenterology. 2004; 127: 1058-66
|
|
|
|
|
|
34) Feinle C, Meier O, Otto B, et al. Role of duodenal lipid and cholecystokinin A receptors in the pathophysiology of functional dyspepsia. Gut. 2001; 48: 347-55
|
|
|
|
|
|
35) Delvaux M, Louvel D, Lagier E, et al. The kappa agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome. Gastroenterology. 1999; 116: 38-45
|
|
|
|
|
|
36) Read NW, Abitbol JL, Bardhan KD, et al. Efficacy and safety of the peripheral kappa agonist fedotozine versus placebo in the treatment of functional dyspepsia. Gut. 1997; 41: 664-8
|
|
|
|
|
|
37) Talley NJ, Choung RS, Camilleri M, et al. Asimadoline, a kappa-opioid agonist, and satiation in functional dyspepsia. Aliment Pharmacol Ther. 2008; 27: 1122-31
|
|
|
|
|